| RS2525294446 |
PPOX
|
Health Risk |
Pathogenic |
Variegate porphyria, childhood-onset |
| RS2525294459 |
DMD
|
Health Risk |
Likely pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2525294536 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2525295490 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2525297168 |
PKLR
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS2525298657 |
PKLR
|
Health Risk |
Likely pathogenic |
— |
| RS2525298832 |
PKLR
|
Health Risk |
Likely pathogenic |
— |
| RS2525298952 |
PBX1
|
Health Risk |
Likely pathogenic |
PBX1-related disorder, PBX1-related disorder |
| RS2525299549 |
PBX1
|
Health Risk |
Pathogenic |
Congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears |
| RS2525299908 |
PBX1
|
Health Risk |
Likely pathogenic |
Congenital anomalies of kidney and urinary tract syndrome with or without hearing loss, abnormal ears |
| RS2525300740 |
COL11A1
|
Health Risk |
Likely pathogenic |
— |
| RS2525301718 |
HFM1
|
Health Risk |
Likely pathogenic |
Premature ovarian failure 9, Premature ovarian failure 9 |
| RS2525303590 |
PKLR
|
Health Risk |
Likely pathogenic |
— |
| RS2525306943 |
PPOX
|
Health Risk |
Pathogenic/Likely pathogenic |
Cardiomyopathy, Cardiomyopathy |
| RS2525310842 |
PEX19
|
Health Risk |
Likely pathogenic |
Peroxisome biogenesis disorder 12A (Zellweger), Peroxisome biogenesis disorder 12A (Zellweger) |
| RS2525310933 |
PEX19
|
Health Risk |
Pathogenic |
Peroxisome biogenesis disorder 12A (Zellweger), Peroxisome biogenesis disorder 12A (Zellweger) |
| RS2525311581 |
CHD5
|
Health Risk |
Likely pathogenic |
Parenti-mignot neurodevelopmental syndrome, Parenti-mignot neurodevelopmental syndrome |
| RS2525311821 |
SPTA1
|
Health Risk |
Pathogenic |
— |
| RS2525313520 |
SPTA1
|
Health Risk |
Likely pathogenic |
— |
| RS2525315768 |
COL11A1
|
Health Risk |
Pathogenic |
— |
| RS2525316064 |
PEX19
|
Health Risk |
Likely pathogenic |
Peroxisome biogenesis disorder 12A (Zellweger), Zellweger spectrum disorders |
| RS2525319078 |
PEX19
|
Health Risk |
Pathogenic |
Peroxisome biogenesis disorder 12A (Zellweger), Peroxisome biogenesis disorder 12A (Zellweger) |
| RS2525324652 |
SPTA1
|
Health Risk |
Likely pathogenic |
— |
| RS2525325352 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2525325369 |
PEX19
|
Health Risk |
Pathogenic |
Peroxisome biogenesis disorder 12A (Zellweger), Peroxisome biogenesis disorder 12A (Zellweger) |
| RS2525327368 |
DMD
|
Health Risk |
Pathogenic |
Duchenne muscular dystrophy, Duchenne muscular dystrophy |
| RS2525328671 |
DMD
|
Health Risk |
Likely pathogenic |
Duchenne and Becker muscular dystrophy, Duchenne and Becker muscular dystrophy |
| RS2525331949 |
SPTA1
|
Health Risk |
Likely pathogenic |
— |
| RS2525336107 |
POMGNT1
|
Health Risk |
Pathogenic/Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 |
| RS2525336277 |
POMGNT1
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 |
| RS2525336723 |
POMGNT1
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 |
| RS2525339224 |
ATF6
|
Health Risk |
Pathogenic |
— |
| RS2525339520 |
ATF6
|
Health Risk |
Pathogenic |
— |
| RS2525343053 |
POMGNT1
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 |
| RS2525344095 |
POMGNT1
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 |
| RS2525344279 |
ATF6
|
Health Risk |
Pathogenic |
— |
| RS2525345067 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525345109 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525345308 |
POMGNT1
|
Health Risk |
Pathogenic |
Autosomal recessive limb-girdle muscular dystrophy type 2O, Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability) |
| RS2525345375 |
POMGNT1
|
Health Risk |
Pathogenic |
Autosomal recessive limb-girdle muscular dystrophy type 2O, Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability) |
| RS2525345840 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525345893 |
PKLR
|
Health Risk |
Likely pathogenic |
Pyruvate kinase deficiency of red cells, Pyruvate kinase deficiency of red cells |
| RS2525347778 |
RCC1
|
Health Risk |
Pathogenic |
See cases, See cases |
| RS2525349586 |
RCC1
|
Health Risk |
Likely pathogenic |
See cases, See cases |
| RS2525350703 |
COL11A1
|
Health Risk |
Likely pathogenic |
— |
| RS2525351411 |
COL11A1
|
Health Risk |
Likely pathogenic |
— |
| RS2525354474 |
DNAJC6
|
Health Risk |
Likely pathogenic |
Juvenile onset Parkinson disease 19A, Juvenile onset Parkinson disease 19A |
| RS2525355372 |
POMGNT1
|
Health Risk |
Pathogenic |
Autosomal recessive limb-girdle muscular dystrophy type 2O, Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability) |
| RS2525355533 |
POMGNT1
|
Health Risk |
Pathogenic |
Autosomal recessive limb-girdle muscular dystrophy type 2O, Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability) |
| RS2525355640 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525360161 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525360440 |
POMGNT1
|
Health Risk |
Likely pathogenic |
POMGNT1-related disorder, Retinitis pigmentosa 76 |
| RS2525360577 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525361367 |
PPOX
|
Health Risk |
Pathogenic/Likely pathogenic |
— |
| RS2525361506 |
PPOX
|
Health Risk |
Pathogenic |
— |
| RS2525362626 |
COL11A1
|
Health Risk |
Pathogenic |
— |
| RS2525363379 |
CHD5
|
Health Risk |
Likely pathogenic |
Parenti-mignot neurodevelopmental syndrome, Parenti-mignot neurodevelopmental syndrome |
| RS2525368687 |
COPA
|
Health Risk |
Likely pathogenic |
Autoimmune interstitial lung disease-arthritis syndrome, Autoimmune interstitial lung disease-arthritis syndrome |
| RS2525370081 |
COL11A1
|
Health Risk |
Conflicting classifications of pathogenicity |
Inborn genetic diseases, Inborn genetic diseases |
| RS2525370664 |
COL11A1
|
Health Risk |
Pathogenic/Likely pathogenic |
Stickler syndrome type 2, Marshall syndrome |
| RS2525370860 |
COL11A1
|
Health Risk |
Likely pathogenic |
— |
| RS2525372237 |
CHD5
|
Health Risk |
Likely pathogenic |
Parenti-mignot neurodevelopmental syndrome, Parenti-mignot neurodevelopmental syndrome |
| RS2525375259 |
TTN
|
Health Risk |
Likely pathogenic |
Autosomal recessive limb-girdle muscular dystrophy type 2J, Dilated cardiomyopathy 1G |
| RS2525378715 |
CHD5
|
Health Risk |
Pathogenic |
— |
| RS2525382839 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525383254 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525383534 |
POMGNT1
|
Health Risk |
Pathogenic |
Autosomal recessive limb-girdle muscular dystrophy type 2O, Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability) |
| RS2525383655 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525384059 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525384071 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525386608 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525386642 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525386670 |
COL11A1
|
Health Risk |
Likely pathogenic |
— |
| RS2525386687 |
COL11A1
|
Health Risk |
Pathogenic |
— |
| RS2525387042 |
CHD5
|
Health Risk |
Likely pathogenic |
Parenti-mignot neurodevelopmental syndrome, Parenti-mignot neurodevelopmental syndrome |
| RS2525387215 |
POMGNT1
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 |
| RS2525387871 |
POMGNT1
|
Health Risk |
Pathogenic/Likely pathogenic |
Autosomal recessive limb-girdle muscular dystrophy type 2O, Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability) |
| RS2525388972 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525389456 |
POMGNT1
|
Health Risk |
Pathogenic/Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525391420 |
SPTA1
|
Health Risk |
Pathogenic |
Hereditary spherocytosis type 3, Hereditary spherocytosis type 3 |
| RS2525391483 |
SPTA1
|
Health Risk |
Likely pathogenic |
Spherocytosis, Spherocytosis |
| RS2525392096 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525395003 |
CHD5
|
Health Risk |
Likely pathogenic |
Parenti-mignot neurodevelopmental syndrome, Parenti-mignot neurodevelopmental syndrome |
| RS2525398475 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 |
| RS2525400290 |
SPTA1
|
Health Risk |
Likely pathogenic |
— |
| RS2525403699 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Autosomal recessive limb-girdle muscular dystrophy type 2O, Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability) |
| RS2525404770 |
COL11A1
|
Health Risk |
Pathogenic |
— |
| RS2525406050 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525406886 |
POMGNT1
|
Health Risk |
Pathogenic |
Autosomal recessive limb-girdle muscular dystrophy type 2O, Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability) |
| RS2525408546 |
COL11A1
|
Health Risk |
Pathogenic |
— |
| RS2525411153 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525411630 |
POMGNT1
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 |
| RS2525412110 |
POMGNT1
|
Health Risk |
Pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 |
| RS2525417527 |
NF1
|
Health Risk |
Pathogenic |
Neurofibromatosis, type 1 |
| RS2525419467 |
CHD5
|
Health Risk |
Likely pathogenic |
— |
| RS2525419753 |
CHD5
|
Health Risk |
Likely pathogenic |
— |
| RS2525424712 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |
| RS2525424719 |
PEX11B
|
Health Risk |
Pathogenic |
— |
| RS2525426371 |
CHD5
|
Health Risk |
Pathogenic |
— |
| RS2525428064 |
POMGNT1
|
Health Risk |
Likely pathogenic |
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 |